Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Breast Care (Basel) ; 17(6): 573-579, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36590144

ABSTRACT

Introduction: Gynecomastia is a benign proliferation of the glandular tissue of the breast in males. Depending on the age, it can be considered a physiological condition. Prepubertal unilateral gynecomastia is a rare phenomenon. There are only a few case reports described through the last few years. Case Presentation: We report the clinical appearance and management of prepubertal idiopathic unilateral gynecomastia in a 9-year-old boy. We further include a literature review of 14 cases from 2011 to 2021. In contrast to pubertal gynecomastia, prepubertal gynecomastia and especially unilateral prepubertal gynecomastia are extremely rare conditions. Most cases remain idiopathic. Conclusion: Chromosomal and genetic testing, as well as oncological, endocrine diagnostic and tests for liver and kidney function should be performed. In case of idiopathic prepubertal gynecomastia, surgery is an important part of therapy since patients suffer from their atypical and rare phenotype.

2.
J Med Genet ; 58(3): 173-176, 2021 03.
Article in English | MEDLINE | ID: mdl-32447323

ABSTRACT

BACKGROUND: The chromosomal region 11p15.5 harbours two imprinting centres (H19/IGF2:IG-DMR/IC1, KCNQ1OT1:TSS-DMR/IC2). Molecular alterations of the IC2 are associated with Beckwith-Wiedemann syndrome (BWS), whereas only single patients with growth retardation and Silver-Russell syndrome (SRS) features have been reported. CNVs in 11p15.5 account for less than 1% of patients with BWS and SRS, and they mainly consist of duplications of both ICs either affecting the maternal (SRS) or the paternal (BWS) allele. However, this correlation does not apply to smaller CNVs, which are associated with diverse clinical outcomes. METHODS AND RESULTS: We identified a family with a 132 bp deletion within the KCNQ1OT1 gene, associated with growth retardation in case of paternal transmission but a normal phenotype when maternally inherited. Comparison of molecular and clinical data with cases from the literature helped to delineate its functional relevance. CONCLUSION: Microdeletions within the paternal IC2 affecting the KCNQ1OT1 gene have been described in only five families, and they all include the differentially methylated region KCNQ1OT1:TSS-DMR/IC2 and parts of the KCNQ1 gene. However, these deletions have different impacts on the expression of both genes and the cell-cycle inhibitor CDKN1C. They thereby cause different phenotypes. The 132 bp deletion is the smallest deletion in the IC2 reported so far. It does not affect the IC2 methylation in general and the coding sequence of the KCNQ1 gene. Thus, the deletion is only associated with a growth retardation phenotype when paternally transmitted but not with other clinical features in case of maternal inheritance as observed for larger deletions.


Subject(s)
Genomic Imprinting/genetics , Growth Disorders/genetics , KCNQ1 Potassium Channel/genetics , Beckwith-Wiedemann Syndrome/epidemiology , Beckwith-Wiedemann Syndrome/genetics , Beckwith-Wiedemann Syndrome/pathology , Child, Preschool , Chromosomes, Human, Pair 11/genetics , DNA Copy Number Variations/genetics , DNA Methylation/genetics , Female , Genetic Predisposition to Disease , Germany , Growth Disorders/epidemiology , Growth Disorders/pathology , Humans , Infant , Insulin-Like Growth Factor II/genetics , Pedigree , Potassium Channels, Voltage-Gated/genetics , RNA, Long Noncoding/genetics , Silver-Russell Syndrome/epidemiology , Silver-Russell Syndrome/genetics , Silver-Russell Syndrome/pathology
4.
Ann Neurol ; 54(5): 686-9, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14595661

ABSTRACT

We report the successful treatment using low-dose vigabatrin (21.5-34 mg/kg/day) of a 10-year-old girl with succinic semialdehyde dehydrogenase (SSADH) deficiency We verified that 4-hydroxybutyric acid (GHB) concentrations in serum, cerebrospinal fluid, and urine continuously decreased in parallel with significant clinical improvement. Our results suggest that GHB quantification in physiological fluids may be a useful laboratory parameter for monitoring efficacy of vigabatrin treatment in SSADH deficiency.


Subject(s)
Aldehyde Oxidoreductases/deficiency , Enzyme Inhibitors/therapeutic use , Hydroxybutyrates/analysis , Metabolism, Inborn Errors/drug therapy , Vigabatrin/therapeutic use , Child , Developmental Disabilities/etiology , Female , Humans , Metabolism, Inborn Errors/physiopathology , Succinate-Semialdehyde Dehydrogenase , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...